News

Spécialisée dans la conception de dispositifs médicaux implantés dans la colonne vertébrale,
la société genevoise regroupe tous ses sites de production haut-savoyards à Reignier.

Affichant une croissance annuelle à deux chiffres, le groupe Spineart déploie une forte présence à l’international, avec pas moins de 60 pays destinataires de ses produits. Et des implantations dans le monde entier : le siège social à Genève, en Haute-Savoie pour la partie production, des bureaux en Europe, en Californie pour le marché américain, ainsi qu’une ouverture prochaine du “Spineart Innovation Center” à Dallas, Texas. «À Plan-les-Ouates (Genève), nous avons la R&D, le marketing et tous les services supports du groupe», détaille Gino Poggiali, directeur administratif et responsable du siège social. Le site est en expansion avec l’ajout de près de 750 m2 de bureaux, dont le bail vient d’être signé. «Nous prévoyons d’embaucher une quarantaine de personnes en plus des 120 actuelles, sur le site de Genève, dans les trois ou quatre ans à venir», complète le PDG du groupe, Jérôme Trividic. Un développement destiné à répondre à la forte croissance de cette société dans le domaine des dispositifs médicaux implantables, qui se situe au douzième rang des entreprises mondiales de ce secteur.

DOUBLER LA CAPACITÉ DE PRODUCTION
En Haute-Savoie, deux sites, Archamps, pour la partie packaging et logistique, et Fillinges, pour la fabrication des pièces, sont en cours de regroupement dans un nouveau bâtiment situé à Reignier qui s’étend sur 4300 m2. Un quasi-doublement de la surface pour répondre à des besoins de production multipliés par deux. Les effectifs seront tous rassemblés sur le même site et devraient passer de 65 à 85 personnes dans les années à venir. «L’investissement rien que pour le bâtiment s’élève à 6,50 millions d’euros », précise Gino Poggiali. «Et près de deux millions pour les machines », ajoute le PDG, notamment des tours et des multi-axes pour l’usinage, et des imprimantes 3D pour le titane poreux. «Une ligne de production complète est d’ores et déjà en fonctionnement dans le but d’obtenir les certifications du site et de l’outil de production», poursuit Jérôme Trividic, pointant les exigences du secteur médical. Un audit est prévu pour fin novembre avec l’obtention du précieux sésame espéré avant la fin du premier trimestre 2025.
«Spineart est une entreprise pilote dans le cadre du Medical Device Regulation (MDR) de l’Union européenne. Les règles ont évolué et la barre est remontée très haut. Nous avons l’expérience car ce règlement a été appliqué pour nos différents sites et produits. Nous arrivons très préparés pour cet audit. »
Le groupe affiche en 20 ans plus de 50 produits lancés et une vingtaine de projets de développement en cours. «Nous avons d’importants investissements stratégiques aux Etats-Unis sur une prothèse de disque cervicale par exemple, dont les études en Europe affichent de très bons retours cliniques », avec la soumission d’une demande d’autorisation de mise sur le marché américain prévue pour 2026.
Ainsi que des innovations sur les aspects robotiques et assistances robotisées dans le médical via des collaborations avec des start-up grenobloises. Autant de développements annonçant une actualité chargée pour ce groupe en pleine expansion dans les mois et les années à venir.

Sandra Molloy

Article de L’Extension – Hiver 2024

Spineart announces that it has reached the significant milestone of 100,000 Ti-LIFE Technology cages sold worldwide, supporting the Company’s mission to transform spine surgery for surgeons, patients and hospitals in more than 60 global markets.

Launched in July 2016, Spineart’s Ti-LIFE Technology is based on a unique proprietary algorithm associated with a state-of-the art additive (3D printing) manufacturing process. Ti-LIFE is applied across a range of Spineart’s surgical implants, including posterior, lateral and cervical cages – hollow interbody devices used in spinal fusion surgeries. These cages act as a space holder between the vertebrae, helping to decompress the spinal cord and nerve root.

Ti-LIFE’s micro-porous structure closely mimics the architecture of the natural trabecular bone and is designed to promote osseous in-growth and cell colonization once implanted. Cages featuring the Ti-LIFE Technology have been shown to outperform other materials, demonstrating early and robust osseointegration without any bone graft or additive osteoinductive agents in just eight weeks.*

“Since its launch in 2016, Spineart’s Ti-Life Technology has contributed significantly to setting a new benchmark in spinal fusion surgery around the world,” remarked Jerome Trividic, Chief Executive Officer at Spineart. “As we progress towards the 20-year anniversary of the founding of our company, this latest milestone reflects our unwavering commitment to transforming spine surgery and improving patient lives, as well as Ti-LIFE’s excellent surgical track record.”

“Spineart’s Ti-LIFE Technology offers significant improvements over traditional titanium implants, with better osseointegration, customizable mechanical properties, and improved imaging capabilities, all of which contribute to enhanced patient outcomes in spinal fusion surgery,” said Joseph Laratta, MD, minimally invasive orthopedic spine surgeon at the Neck and Back Institute of Kentucky.

“Surpassing the 100,000 sales milestone for our Ti-LIFE Technology cages is a powerful demonstration of our strong growth to date as well as our future potential. Thank you to our team, investors, partners, surgeons and customers, each of whom have worked alongside us to reach this goal,” added Alessia Erlingher, Chief Commercial Officer at Spineart.

To learn more about Ti-LIFE Technology: https://www.spineart.com/technology/ti-life-technology/

References:

* Joseph L. Laratta, MD et al. 3D-printed titanium cages without bone graft outperform PEEK cages with autograft in an animal model. The Spine Journal. 2021; DOI.

Dallas, Texas, November 12, 2024 – Spineart, a leader in spine surgery innovation, unveils the Spineart Innovation Center in Dallas, Texas with a grand opening date of Thursday, November 14, 2024.

The Spineart Innovation Center is a 5,500-square-foot facility located at Trinity Towers. This state-of-the-art facility is designed for spine surgeons, hospitals, and academic institutions to enhance learning and collaboration. The center includes sweeping views of the Dallas skyline, conference meeting space, offices, and a 1,300-square-foot wet lab. The lab features two cadaveric stations, one equipped with the eCential Robotics platform, designed as a single system integrating 2D/3D imaging, navigation, robotics, and customized Spineart applications.

“The opening of the Spineart Innovation Center is a significant milestone.” said Jerome Trividic, CEO of Spineart. “It will enable us to provide spine surgeons with access to next-generation navigation and robotics technologies that represent the cutting edge of spine surgery. In addition, the center will welcome local institutions, providing opportunities to collaborate on research and development projects and participate in fully customized training programs.”

Dallas was selected for the Spineart Innovation Center due to its status as a major domestic and international hub. Dallas has become a powerhouse for tech innovation, supported by a business-friendly environment and diverse talent pool in engineering. This location provides Spineart with several advantages aligned with the Company’s goal of establishing a hub for innovation and training in robotic spine surgery, including access to a robust medical community and opportunities for potential collaborations with local institutions.

With great enthusiasm, Laurent Nodé-Langlois, Chief Technology Officer at Spineart, shared, “After 20 years of pioneering hardware development at Spineart, we’re now stepping into the digital realm, shaping the future of spine surgery.”

“From think tanks to hands-on product trials, we are ready to push the boundaries of research and development” said Alessia Erlingher, Chief Commercial Officer of Spineart. “By partnering with leading hospitals and surgeons, we’re not only advancing medical science but also ensuring better outcomes for patients everywhere.”

ORANGE, Calif. July 25, 2024 – Providence St. Joseph Hospital announced it has successfully performed the world’s first robotic spinal surgery using a new open spine platform by eCential Robotics to implant a Spineart medical device.

eCential Robotics, a surgical robotics company which developed the open surgical platform and Spineart, a leader in spine surgery innovation, are collaborators in a new age of open technology sharing that allows cross-functional use of implantation devices and robotic surgical platforms.

“In our relentless pursuit of innovation and excellence in patient care, we were eager to utilize the solutions provided by Spineart and eCential,” said Erick Westbroek*, M.D., Providence St. Joseph spinal surgeon. “The integration of Spineart’s advanced implant system with eCential’s open robotic platform will enable us to perform minimally invasive surgeries with high predictability, reproducibility and outcomes.”

Providence St. Joseph Hospital has become the first clinical institution in the world to be equipped with the state-of-the-art robot, and the recent surgeries are the first in the United States to be used successfully in conjunction with Spineart implants.

“St. Joseph Hospital has built a strong reputation for world-class surgical care, and our patients often travel from far and wide to seek treatment and care from our stellar spine and orthopedic surgeons, who are armed with cutting-edge technology,” said Brian Helleland, chief executive of Providence St. Joseph Hospital and the Orange County/High Desert area. “These advances provide yet another sophisticated platform for our surgeons to do what they do best.”

“We are thrilled to announce the installation of this state-of-the-art robot at St. Joseph Hospital,” said Jerome Trividic, CEO of Spineart. “We believe this advancement will greatly benefit our customers, hospitals, surgeons, and patients by enhancing surgical precision and improving patient outcomes.”

St. Joseph’s surgical cases for eCential Robotics are a first-in-human use of its unified robotic technology, as well as the start of eCential operations in the US. It also marks the introduction of cutting-edge solutions that address the evolving needs of surgeons and patients worldwide.

“We are pleased to see the adoption of our technology in the US,” Clément Vidal, CEO of eCential Robotics. “There is strong interest and momentum for our open solution because it allows surgeons to select the optimal implant system for each patient while providing financial advantages to hospitals. Our platform is described as the smartphone of surgical robots.”

* Dr. Erick Westbroek is a paid consultant of Spineart. His statements represent his own opinions based on personal experience and are not necessarily those of Spineart.

Geneva, Switzerland – June 28, 2024 – Spineart, a fast-growing company specialized in spine surgery innovation, is pleased to announce the appointment of Laurent Nodé-Langlois as Chief Technology Officer.

In his new role, Laurent will be based in the United States and will lead Spineart’s strategic initiatives in enabling technologies, focusing on digital surgical planning, navigation and robotics.

Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at General Electric, playing a pivotal role in advancing GE Healthcare’s 3D imaging and navigation technologies.

“We are delighted to welcome Laurent Nodé-Langlois to Spineart as our Chief Technology Officer,” said Jerome Trividic, CEO of Spineart. “His extensive expertise and proven track record in leading transformative advancements in enabling technologies will be instrumental as we continue to innovate and expand our capabilities in spine surgery.”

As Chief Technology Officer, Laurent will oversee Spineart’s enabling technologies strategy, including managing our investments and collaborations with healthtech and deeptech startups, as well as enhancing Spineart’s intellectual property portfolio. This strategic new Executive role underlines Spineart’s commitment to deliver cutting-edge solutions for spine surgeons worldwide.

“I am excited to join Spineart and lead the Enabling Technologies business unit at such a pivotal time in the industry,” said Laurent Nodé-Langlois. “I look forward to leveraging my experience and collaborating with the talented team at Spineart and their partners to advance our technological capabilities and drive innovation that improves patient outcomes.”

Spineart proudly announces the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SCARLET® AC-Ti secured anterior cervical cage.

The SCARLET® AC-Ti builds on a decade of experience with the SCARLET® system. The SCARLET® AC-Ti addition introduces new features such as the MIMETIX® morphometric profile, developed with digital models of the vertebrae to optimize the contact surface between implant and endplates. The system allows for fixation with screws and anchors.

The SCARLET® AC-Ti cervical cage utilizes Spineart’s proprietary Ti-LIFE technology¹. Ti-LIFE technology, a proprietary additive manufacturing process, has a porous structure that closely mimics the trabecular bone structure.

“This approval underscores our commitment to innovation, continuously evolving our most successful products, such as the SCARLET® system” said Alessia Erlingher, Chief Commercial Officer at Spineart.